Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multinational, Multicenter, Retrospective Study to Evaluate an AI/ML Technology-Based End-to-End CADe/CADx SaMD, Which Allows Detection, Localization and Characterization of Pulmonary Nodules (REALITY)

NCT06576232 is registered in ClinicalTrials.gov with Median Technologies as lead sponsor.

NCT NCT06576232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06576232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multinational, Multicenter, Retrospective Study to Evaluate an AI/ML Technology-Based End-to-End CADe/CADx SaMD, Which Allows Detection, Localization and Characterization of Pulmonary Nodules (REALITY)
Lead sponsor
Median Technologies
Phase
Observational
Overall status
Completed
Start date
September 21, 2022
Completion date
August 21, 2024
Enrollment
1,147 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

high risk cancer